RNA vs. DNA Fusion Reference Standards: Which Does Your Assay Need?

An RNA fusion assay and a DNA fusion assay may report the same gene pair while examining different molecular targets. That distinction matters when choosing fusion reference standards: a control containing a fusion transcript may not contain the corresponding genomic rearrangement, and a DNA-positive material does not by itself demonstrate a detectable RNA transcript.

For assay developers and molecular laboratories, the starting point is the measurement. This guide compares RNA and DNA fusion controls, explains why they are not automatically interchangeable, and shows what to confirm when a workflow uses both.

Quick Answer

• Use RNA fusion reference standards for assays that start with RNA and detect fusion transcripts.

• Use DNA fusion reference standards for assays that interrogate genomic rearrangements.

• Characterize both targets before sharing one control across a combined DNA/RNA workflow.

• Treat the fusion name as a starting point; confirm the target sequence and workflow for each use.

RNA vs. DNA Fusion Reference Standards at a Glance

DNA-based fusion testing investigates rearranged genomic sequences. RNA-based fusion testing investigates transcribed fusion sequences, commonly identified through junctions between exons of the partner genes. These are related layers of information, with different requirements for control selection.

When comparing fusion reference standards, identify the nucleic acid target first. Then match the individual material to the relevant branch of your assay.

Understand Genomic Breakpoints and RNA Junctions

DNA Controls Must Match the Genomic Target

Genomic fusion breakpoints can occur at different locations, including intronic regions. For targeted DNA sequencing, the position of the breakpoint and the regions included in the assay design affect detection.

A DNA control therefore needs more detail than a fusion partner pair. For a breakpoint-specific assay, confirm the breakpoint-spanning sequence. For a targeted NGS panel, confirm that the relevant rearrangement falls within the assay’s detection scope.

Review genomic coordinates together with the reference assembly used to describe them. Resolve any annotation differences before using the material to set expected results. An exon-level RNA description is not a complete specification of a genomic DNA breakpoint.

RNA Controls Must Match the Transcript Target

RNA fusion testing examines the transcript produced from the fusion, rather than directly measuring its causal genomic rearrangement. Fusion transcripts can have alternative isoforms, so the partner names alone do not fully describe the RNA target.

For example, EML4 exon 13–ALK exon 20 and EML4 exon 6–ALK exon 20 represent different transcript junctions. A junction-specific RT-qPCR assay needs a control containing its intended junction. A broader RNA panel still needs the appropriate target sequence and enrichment coverage.

Request the transcript accession and version, exon junction, or sequence needed to make that match. Keep the RNA annotation and the genomic breakpoint description as separate entries in your control records.

Why an RNA-Positive Control May Not Be a DNA-Positive Control

The construction of a reference material determines which targets it contains. Engineered materials can include fusion RNA without the corresponding chromosomal translocation. This has been demonstrated in an FFPE fusion RNA material made by introducing in vitro transcribed RNA constructs into background cells.

Consequently, an RNA-positive result cannot be used as evidence that the same material contains the genomic breakpoint required by your DNA assay.

The label “cell-derived” does not resolve this question. RNA expression can be engineered through an introduced expression construct. That approach is different from reproducing the native chromosomal rearrangement; the specific DNA target still needs its own characterization.

Before using one material for both methods, confirm:

• Which genomic rearrangement or DNA sequence is present.

• Which fusion transcript or RNA junction is present.

• How each target was verified.

• Which quantitative values apply to each nucleic acid.

The reverse assumption also needs checking. A characterized DNA rearrangement does not guarantee a detectable RNA result under a particular assay. Expression, transcript coverage, and RNA quality can affect that result. Research comparing DNA and RNA fusion testing has documented discordant findings between the two methods.

Choose Controls for the Assay You Actually Run

[Insert Image 1 here — conceptual illustration of verifying RNA and DNA control identities against documentation. Alt: A laboratory worker checks an RNA reference tube beside a DNA tube and a documentation checklist.]

RNA-Based NGS, RT-qPCR, and RT-dPCR

Select an RNA material containing the intended fusion transcript and suitable for your method’s input requirements. It should challenge the RNA-dependent steps you want to evaluate.

A cDNA control starts after reverse transcription. It can help assess downstream amplification, but it does not evaluate the conversion of RNA to cDNA. That distinction matters because reverse transcription can introduce uncertainty and bias into quantitative RNA measurements.

Check the workflow entry point as well. Purified RNA starts after extraction. If the study includes extraction, use a suitable material that passes through that step; an appropriate FFPE fusion RNA material can support an FFPE extraction workflow.

DNA-Based NGS and Genomic Breakpoint PCR

Select a DNA material with the rearranged sequence needed by the assay. Confirm the genomic target and its overlap with your amplification or enrichment design.

A DNA construct containing a sequence copied from a mature fusion transcript is not automatically a control for the native genomic breakpoint. Its suitability depends on whether it contains the actual sequence your DNA assay interrogates.

Also align the material format with the study. Purified DNA can enter after extraction; evaluation of extraction requires an appropriate sample-like starting material. Define that requirement separately from the fusion target.

Combined DNA/RNA Workflows

A combined assay needs evidence for the DNA and RNA branches separately. A published integrated fusion assay validation used DNA and RNA reference standards and assessed the performance of each branch with its corresponding measurements.

You can use separate materials or a material characterized for both targets. In either case, document expected DNA calls and expected RNA calls independently. Do not accept a passing result from one branch as verification of the other.

If you are considering cell-derived fusion control customization, specify whether you need a genomic rearrangement, an expressed transcript, or both. Request confirmation of the proposed construction and characterization before finalizing the material.

Keep DNA Allele Fraction and RNA Abundance Separate

DNA allele fraction and RNA fusion abundance describe different quantities. For DNA, review how the rearranged target is measured relative to the specified denominator. For RNA, review target-specific abundance and whether the result is expressed as copies per RNA mass, volume, or reaction.

There is no general conversion from a DNA fusion allele fraction to RNA transcript copies. Likewise, an RNA assay’s reported fraction should not be treated as a DNA allele fraction without defining what each measurement represents.

NGS read counts are also distinct from absolute transcript copy numbers. In an RNA fusion validation study, the relationship between these quantities differed among targets.

Set expected values and acceptance criteria for the relevant measurement. Comparing differently defined quantities can create an apparent discrepancy even when the materials are being measured at different molecular levels.

Confirm Both Targets Before Sharing a Material Across Methods

For a control intended to support more than one method, request a characterization summary that separates the required evidence:

If DNA break-apart FISH is also involved, confirm suitability for that specific probe design and specimen format. Such assays detect genomic rearrangements in prepared specimens; an RNA-positive tube does not establish the required FISH signal pattern.

Keep the control’s purpose explicit in laboratory records. “Fusion positive” should be accompanied by the nucleic acid, target description, and method for which positivity has been established.

Conclusion

Choose RNA or DNA fusion reference standards according to the molecular target your assay measures. RNA controls address fusion transcripts; DNA controls address specified genomic targets. For a combined workflow, confirm both independently and interpret their quantitative results using the appropriate units. A shared fusion name alone is insufficient to make the materials interchangeable.

Discuss the Molecular Targets Your Assay Needs

Share your fusion partners, genomic breakpoint or RNA junction, assay method, and required material format with CB-Gene. Contact our team to discuss available reference material options and the characterization documents needed for your study.

Frequently Asked Questions

Are RNA and DNA Fusion Reference Standards Interchangeable?

Only when the material contains the relevant targets and has been characterized for each intended method. RNA positivity alone does not confirm the genomic DNA target needed by a DNA fusion assay.

Can RNA Fusion Reference Standards Verify a DNA NGS Panel?

An RNA-only material cannot serve as the positive DNA control for a genomic fusion target. Choose a material with documented DNA target identity and coverage relevant to the panel.

Can a cDNA Control Replace RNA in an RT-qPCR Study?

A cDNA control can evaluate downstream PCR steps. Use an appropriate RNA control when the study must also assess reverse transcription.

Does a DNA Fusion Allele Fraction Predict RNA Transcript Abundance?

It does not provide a general prediction. The DNA measurement describes a genomic target ratio, while the RNA result reflects the specified transcript and its measurement conditions.

Can One FFPE Fusion Control Support RNA Testing and DNA FISH?

Possibly, if it contains the necessary targets and is characterized for both uses. Confirm the RNA transcript and the rearrangement required by the DNA FISH probe; FFPE format alone does not establish both.